Anne B Chang, Stephanie T Yerkovich, Katherine J Baines, Lucy Burr, Anita Champion, Mark D Chatfield, Kah P Eg, Vikas Goyal, Robyn L Marsh, Gabrielle B McCallum, Margaret McElrea, Steven McPhail, Lucy C Morgan, Peter S Morris, Anne M Nathan, Hannah O'Farrell, Marion O Sanchez, Marianne Parsons, André Schultz, Paul J Torzillo, Nicholas P West, Lesley Versteegh, Julie M Marchant, Keith Grimwood
INTRODUCTION: Bronchiectasis is a worldwide chronic lung disorder where exacerbations are common. It affects people of all ages, but especially Indigenous populations in high-income nations. Despite being a major contributor to chronic lung disease, there are no licensed therapies for bronchiectasis and there remain relatively few randomised controlled trials (RCTs) conducted in children and adults. Our RCT will address some of these unmet needs by evaluating whether the novel mucoactive agent, erdosteine, has a therapeutic role in children and adults with bronchiectasis...
May 7, 2024: BMJ Open Respiratory Research